HeartBeam to Host Q3 2025 Conference Call on November 13

HeartBeam Inc. (NASDAQ: BEAT) has scheduled its third quarter 2025 conference call for November 13, 2025, at 4:30 p.m. ET, where the medical technology company will discuss financial results for the period ended September 30, 2025. The company will also provide significant updates on regulatory progress, commercial-readiness activities, and upcoming milestones that could substantially impact the future of cardiac care. This announcement matters because HeartBeam is developing transformative technology that could revolutionize how cardiac conditions are detected and monitored outside traditional medical facilities.

The importance of this conference call extends beyond typical quarterly financial reporting, as HeartBeam is positioned to disrupt cardiac care through its innovative 3D ECG technology platform. The company holds over 20 issued patents related to technology enablement and has already achieved a critical regulatory milestone with FDA clearance for arrhythmia assessment in December 2024. Currently, the company's 12-Lead ECG synthesis software remains under FDA review, making regulatory updates during the conference call particularly significant for investors and the medical community.

HeartBeam's technology represents a fundamental shift in cardiac monitoring by creating the first-ever cable-free device capable of collecting ECG signals in three dimensions from non-coplanar directions and synthesizing these signals into a 12-lead ECG. This breakthrough matters because it enables portable devices that can be used wherever patients are located, delivering actionable heart intelligence directly to physicians. The implications are substantial for improving cardiac health management by allowing physicians to identify cardiac health trends and acute conditions outside medical facilities, potentially reducing hospital visits and enabling earlier intervention.

The upcoming conference call will provide crucial insights into the company's progress toward commercializing this transformative technology. Investors and stakeholders can access detailed information through the company's newsroom available at https://ibn.fm/BEAT, where the latest updates relating to BEAT are maintained. The timing of this announcement coincides with increasing focus on remote patient monitoring and telehealth solutions, positioning HeartBeam's technology as potentially disruptive in the evolving healthcare landscape. The company's ability to execute on its regulatory and commercial milestones could have far-reaching implications for how cardiac conditions are managed globally.